Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: Risk factors and response to treatment

Bone Marrow Transplantation

Volumn 48, Issue 7, 2013, Pages 926-931

  Kanda, J ^a,b   Kaynar, L ^a,c   Kanda, Y ^b   Prasad, V K ^a   Parikh, S H ^a   Lan, L ^d   Shen, T ^d   Rizzieri, D A ^a   Long, G D ^a   Sullivan, K M ^a   Gasparetto, C ^a   Chute, J P ^a   Morris, A ^a   Winkel, S ^a   McPherson, J ^a   Kurtzberg, J ^a   Chao, N J ^a   Horwitz, M E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c ERCIYES UNIVERSITY   (Turkey)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dual umbilical cord blood transplantation; myeloablative; pre engraftment syndrome

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG RESPONSE; ENGRAFTMENT SYNDROME; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PREENGRAFTMENT SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FEVER; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEUTROPHILS; RISK FACTORS; SYNDROME; TACROLIMUS; TRANSPLANTATION CONDITIONING;

EID: 84880212593     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.279     Document Type: Article

References (18)

1. Kishi Y, Kami M, Miyakoshi S, Kanda Y, Murashige N, Teshima T et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation 2005; 80: 34-40.
2. Patel KJ, Rice RD, Hawke R, Abboud M, Heller G, Scaradavou A et al. Preengraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: 435-440.
3. Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, Tsuji M et al. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. Transplantation 2011; 92: 366-371.
4. Narimatsu H, Terakura S, Matsuo K, Oba T, Uchida T, Iida H et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transplant 2007; 39: 31-39.
5. Frangoul H, Wang L, Harrell Jr FE, Ho R, Domm J. Preengraftment syndrome after unrelated cord blood transplant is a strong predictor of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 1485-1488.
6. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
7. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
8. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
9. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
10. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
11. Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181-185.
12. Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant 2004; 34: 331-337.
13. Inamoto Y, Flowers ME, Appelbaum FR, Carpenter PA, Deeg HJ, Furlong T et al. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. Biol Blood Marrow Transplant 2011; 17: 1088-1092.
14. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893-898.
15. Maiolino A, Biasoli I, Lima J, Portugal AC, Pulcheri W, Nucci M. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transplant 2003; 31: 393-397.
16. Sullivan KM, Deeg HJ, Sanders J, Klosterman A, Amos D, Shulman H et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986; 67: 1172-1175.
17. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007; 109: 2751-2758.
18. Morita-Hoshi Y, Mori SI, Soeda A, Wakeda T, Ohsaki Y, Shiwa M et al. Identification of molecular markers for pre-engraftment immune reactions after cord blood transplantation by SELDI-TOF MS. Bone Marrow Transplant 2010; 45: 1594-1601.